JP2022548364A5 - - Google Patents

Info

Publication number
JP2022548364A5
JP2022548364A5 JP2022516618A JP2022516618A JP2022548364A5 JP 2022548364 A5 JP2022548364 A5 JP 2022548364A5 JP 2022516618 A JP2022516618 A JP 2022516618A JP 2022516618 A JP2022516618 A JP 2022516618A JP 2022548364 A5 JP2022548364 A5 JP 2022548364A5
Authority
JP
Japan
Prior art keywords
sequence
fusion protein
cancer
variant
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022516618A
Other languages
English (en)
Japanese (ja)
Other versions
JP7822620B2 (ja
JP2022548364A (ja
Filing date
Publication date
Priority claimed from EP19198358.4A external-priority patent/EP3795583A1/en
Application filed filed Critical
Publication of JP2022548364A publication Critical patent/JP2022548364A/ja
Publication of JP2022548364A5 publication Critical patent/JP2022548364A5/ja
Application granted granted Critical
Publication of JP7822620B2 publication Critical patent/JP7822620B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022516618A 2019-09-19 2020-09-18 免疫療法のエンハンサーとして有用なil-10/fc融合タンパク質 Active JP7822620B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19198358.4 2019-09-19
EP19198358.4A EP3795583A1 (en) 2019-09-19 2019-09-19 Il10/fc fusion proteins useful as enhancers of immunotherapies
PCT/EP2020/076089 WO2021053134A1 (en) 2019-09-19 2020-09-18 Il-10/fc fusion proteins useful as enhancers of immunotherapies

Publications (3)

Publication Number Publication Date
JP2022548364A JP2022548364A (ja) 2022-11-18
JP2022548364A5 true JP2022548364A5 (cg-RX-API-DMAC7.html) 2023-09-11
JP7822620B2 JP7822620B2 (ja) 2026-03-03

Family

ID=68069476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516618A Active JP7822620B2 (ja) 2019-09-19 2020-09-18 免疫療法のエンハンサーとして有用なil-10/fc融合タンパク質

Country Status (10)

Country Link
US (1) US20220370564A1 (cg-RX-API-DMAC7.html)
EP (2) EP3795583A1 (cg-RX-API-DMAC7.html)
JP (1) JP7822620B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220065839A (cg-RX-API-DMAC7.html)
CN (1) CN114728041A (cg-RX-API-DMAC7.html)
AU (1) AU2020351062B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022005159A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150050A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022003417A (cg-RX-API-DMAC7.html)
WO (1) WO2021053134A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230009430A (ko) * 2020-05-12 2023-01-17 리제너론 파아마슈티컬스, 인크. 신규 il10 효능제 및 그의 사용 방법
EP4200405A1 (en) * 2020-08-21 2023-06-28 Université de Lausanne Mpc inhibition for producing t-cells with a memory phenotype
EP4285913A1 (en) * 2022-05-30 2023-12-06 Ecole Polytechnique Fédérale de Lausanne (EPFL) Highly effective adoptive t cell therapy
WO2024249957A2 (en) * 2023-06-01 2024-12-05 Synthekine, Inc. Il10 inverted monomers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
EP3053932B1 (en) * 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
CN101948543B (zh) 2010-08-30 2013-01-16 中国科学技术大学 一种融合蛋白及其编码基因与应用
RU2639526C2 (ru) 2011-06-28 2017-12-21 ИНХИБРКС ЭлЭлСи Слитые полипептиды, содержащие домен wap, и способы их применения
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
EP3233920B1 (en) 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
WO2017087784A1 (en) * 2015-11-18 2017-05-26 Duke University Tumor infiltrating lymphocytes for treatment of cancer
WO2018005226A2 (en) * 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技(上海)有限公司 制备融合蛋白的方法
BR112019007100A2 (pt) * 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CN108948207B (zh) 2017-05-22 2020-11-13 杭州博虎生物科技有限公司 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
JP7356726B2 (ja) * 2017-09-25 2023-10-05 ディンフー バイオターゲット カンパニー リミテッド タンパク性ヘテロ二量体及びその使用

Similar Documents

Publication Publication Date Title
JP2023506454A5 (cg-RX-API-DMAC7.html)
JP2024500847A5 (cg-RX-API-DMAC7.html)
JP2021113191A (ja) メイタンシノイド誘導体、そのコンジュゲート、及び使用方法
ES2711377T3 (es) Molécula Fv de unión a antígenos multivalente
CN117042806A (zh) 抗体-免疫激动剂缀合物及其应用
JP2019531697A5 (cg-RX-API-DMAC7.html)
JP2019531728A5 (cg-RX-API-DMAC7.html)
JP2020529864A5 (cg-RX-API-DMAC7.html)
Mahmoudi et al. Recombinant immunotoxins development for HER2-based targeted cancer therapies
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
WO2018127175A1 (zh) 抗5t4抗体-药物偶联物及其应用
JP2020521478A5 (cg-RX-API-DMAC7.html)
TW201609152A (zh) 包含細胞結合劑及細胞毒性劑之偶聯物
CN117946278A (zh) 多特异性抗体及其制备和使用方法
JP2016519651A5 (cg-RX-API-DMAC7.html)
JP7811217B2 (ja) 抗her2抗体-免疫アゴニストコンジュゲート及びその使用
CA2560278A1 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
JP2024531446A5 (cg-RX-API-DMAC7.html)
CN108430511A (zh) 一种药物设计方法和获得的药物及其应用
CN115052663A (zh) Alk5抑制剂缀合物及其用途
CN115916839A (zh) 抗pdl1×egfr的双特异性抗体
KR20240082324A (ko) 면역 관문 분자와 결합 가능한 분자가 융합된 단백질 및 이의 용도
Schaedel et al. Antibodies and their fragments as anti-cancer agents
Roshan et al. A novel immunotoxin targeting epithelial cell adhesion molecule using single domain antibody fused to diphtheria toxin
CN111278462A (zh) 抗egfr抗体药物结合物(adc)和其用途